Ewing sarcoma therapeutics market seen reaching $0.88 billion by 2030

The Business Research Company says the global market for Ewing sarcoma therapies will grow from $0.6 billion in 2025 to $0.65 billion in 2026, then to $0.88 billion by 2030. The forecast points to precision medicine, targeted therapies and rising healthcare spending as the main growth drivers for this rare cancer segment.

Why it matters: - Ewing sarcoma is a rare and aggressive cancer that mainly affects children, adolescents and young adults. - The market outlook signals more demand for diagnostics, oncology infrastructure and specialized treatments in a small but fast-developing rare-cancer segment.

What happened: - The Business Research Company published its Global Market Report 2026 for the Ewing sarcoma therapeutics market. - The report estimates the market will rise from $0.6 billion in 2025 to $0.65 billion in 2026. - The report projects the market will reach $0.88 billion by 2030. - The company said the market will grow at a 7.6% CAGR from 2025 to 2026 and a 7.9% CAGR through 2030. - North America held the largest regional share in 2025. - Asia-Pacific is forecast to be the fastest-growing region in the coming years.

The details: - The report links past growth to more pediatric bone cancer cases, wider use of chemotherapy-based treatments, better oncology hospital infrastructure, higher awareness of rare cancer diagnoses and standard multimodal treatment protocols. - The report says future growth will be driven by precision medicine, genomic profiling, more clinical trials in rare sarcoma therapies, expanded targeted drug pipelines, higher investment in pediatric oncology research and broader use of immunotherapy and biologic treatments. - Ewing sarcoma therapeutics include medicines and treatments used to manage cancers of the bones and soft tissues. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company added new 2026 report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - A free sample report is available here. - The full report is available here.

Between the lines: - The forecast suggests rare-cancer drug development is moving toward more personalized treatment models. - The market’s growth rate remains modest in absolute dollar terms, but the focus on precision medicine and targeted therapies points to a broader shift in how rare cancers are researched and treated. - Rising healthcare spending supports access to advanced cancer care and can help fund clinical research and infrastructure.

What's next: - The market is expected to continue expanding through 2030 if precision medicine, immunotherapy and targeted therapy pipelines keep advancing. - More clinical trial activity and pediatric oncology investment could shape the next phase of competition in this market. - Regional growth may increasingly shift toward Asia-Pacific as adoption and research activity widen.